This episode breaks down Merck, a $300B pharma giant whose engine is Keytruda, a cancer drug that brings in $25B a year. The guest argues Keytruda's real moat isn't its patent but clinical data covering 40 cancer types—making it hard for insurers to swap in cheaper rivals. But Keytruda's patent expires in 2028, and history shows pharma companies struggle after such cliffs. Key holdings: Keytruda (40% of Merck's revenue), Gardasil (HPV vaccine, $8.8B, nearly wiped out cervical cancer), and Sotatercept (a new drug for pulmonary hypertension, bought for $11B, but sales estimates vary wildly).
Merck (market cap ~$300 billion) is one of the oldest and largest pharmaceutical companies in the world. Its core growth engine is the cancer drug Keytruda, which generates over $25 billion in annual revenue and is widely regarded as the most important cancer drug globally. The report provides an in
Guest Ashwin Varma (medical student, former Celgene immuno-oncology business development analyst who worked alongside immuno-oncology pioneer Jim Allison) deconstructs Merck — a pharmaceutical giant with a market cap of nearly $300 billion, driven by Keytruda as its core engine. The most impactful takeaway of the entire episode: Keytruda’s true moat is not the patent itself, but the breadth of clinical data covering 40 indications — which gives it unmatched pricing power in negotiations with PBMs, a position no other PD-1 drug can rival.
Ashwin Varma points out that Merck’s history is a recurring cycle of "innovation explosion → pipeline depletion → restructuring and rebirth."
Golden Age (1980s–1990s): Under CEO Roy Vagelos (a scientist by training), Merck launched a series of blockbuster drugs—statins, ACE inhibitors, proton pump inhibitors—that remain in medical school textbooks today. Sales surged from less than $2 billion in 1980 to $40 billion in 2000.
Dark Decade (2000–2010): Pipeline depletion, a string of clinical trial failures, and the Vioxx litigation scandal drove the stock down roughly 40%, while sales shrank from $40 billion to $27 billion.
Rebirth (2010–present): Through an acquisition, Merck obtained Keytruda (originally owned by another company) and, via the largest and most brilliantly executed clinical trial campaign in history, turned it into the world’s most important oncology drug, generating over $25 billion in annual revenue.
Key Insight: Merck now stands at another patent cliff—Keytruda’s core patents are expected to expire in 2028. Historical patterns show that large pharmaceutical companies have a very low "base success rate" in navigating patent cliffs (Pfizer struggled similarly after Lipitor’s patent expired).
Ashwin Varma breaks down the analytical framework for pharmaceutical companies into three core levers: pipeline quality, commercialization potential, and IP protection status.
| Dimension | Small Molecule Drugs | Biologics (e.g., Keytruda) |
|---|---|---|
| Manufacturing Method | Chemical synthesis, very low cost (~$5/vial) | Produced in living cell bioreactors, ~$150/gram |
| Difficulty of Generic Competition After Patent Expiry | Easy (low-cost verification of equivalence) | Difficult (cannot simply prove bioequivalence) |
| Typical Revenue Erosion Speed | 80% disappears within 8 months (e.g., Seroquel) | Slower, can persist for years (e.g., insulin) |
| Patent Portfolio Complexity | Smaller | Large (sequence patents + formulation patents + process patents) |
Ashwin Varma emphasizes: Patents only provide the "floor" for pricing power; what truly determines pricing ability is the breadth of clinical data.
Ashwin Varma believes Keytruda’s success is a classic case of “luck plus execution.”
Ashwin Varma believes the threat from Summit Therapeutics’ new drug (PD-1/VEGF bispecific antibody) to Keytruda is overstated, for the following reasons:
1. Its Chinese trial data is not recognized by the FDA for U.S. approval, requiring an additional two years to redo the study.
2. The trial design did not use a chemotherapy combination (the U.S. standard of care), making it an unfair comparison.
3. Similar combination therapies have already been attempted in the U.S., with results showing no significant superiority.
The real threat is the pace of revenue erosion after the patent expires in 2028.
Ashwin Varma believes Merck's management has taken proactive steps, but historical patterns show that the patent cliff period is extremely challenging.
| Pillar | Source | Indication | Potential Peak Sales | Risk |
|---|---|---|---|---|
| Sotatercept | Acquisition of Acceleron in 2021 ($11 billion) | Pulmonary Arterial Hypertension | $2–9 billion (wide consensus divergence) | Highly uncertain forecasts |
| PRA023 (Prometheus) | Acquisition of Prometheus in 2023 | Ulcerative Colitis / Crohn's Disease | Not disclosed | Intense competition (Humira + second-generation drugs already occupy the market) |
| Antibody-Drug Conjugates (ADC) | Acquisition of Velos Bio ($3 billion) + Partnership with Daiichi ($4 billion) | Multiple cancers | Not disclosed | Still in Phase II, high clinical risk |
Ashwin Varma acknowledges that management recognizes "it is difficult to replicate success in areas where success has already been achieved," hence the shift toward non-oncology indications (pulmonary arterial hypertension, autoimmune diseases). However, he also notes that the partnership between CEO Robert Davis and R&D head Dean Lee has yet to be proven—historically, Merck's most successful period (Frazier + Perlmutter) was characterized by close collaboration between the CEO and the head of R&D.
Ashwin Varma emphasizes that success in large pharmaceutical companies rarely depends on a single CEO, but rather on the chemistry between the CEO and the R&D head.
Organizational structure: Large pharma companies are typically divided into R&D (preclinical research + clinical trials) and commercialization (marketing + sales + regulatory) branches. Due to Keytruda's continuous expansion of indications, the two branches have operated in parallel over the long term.
| Position | Analyst View | Key Data |
|---|---|---|
| Keytruda (Merck's core product) | Bullish (but flags 2028 patent expiry risk) | Annual revenue $25B, ~40% of Merck's total revenue, covering 40 indications, list price $191,000/year |
| Gardasil (Merck's vaccine) | Positive mention | 2023 revenue $8.8B, nearly eliminated HPV-related cancers |
| Opdivo (BMS) | Competitive comparison | Formerly Keytruda's main rival, fell behind after a failed 2016 lung cancer trial |
| Sotatercept (Merck acquired via Acceleron) | Cautiously optimistic | Acquisition cost $11B, consensus peak estimate $2-9B (wide divergence) |
| PRA023 (Merck acquired via Prometheus) | Neutral (competitive risk flagged) | Targets ulcerative colitis/Crohn's disease, crowded market |
| ADC pipeline (Merck in-house + partnership with Daiichi) | Bullish but early-stage | Acquired Velos Bio ($3B) + partnership with Daiichi ($4B), still in Phase II |
| Humira (AbbVie) | Mentioned as analogy | Maintained revenue despite biosimilar competition, but political pressure increasing |
| Summit Therapeutics' new drug | Threat overstated | Chinese trial PFS 11 months vs Keytruda 5 months, but data not comparable |
1. Keytruda's true moat is not its patents, but the breadth of clinical data across 40 indications — this prevents PBMs from substituting it with other PD-1 drugs, thereby maintaining net prices close to the list price. (Ashwin Varma)
2. Merck overtook BMS, which had a 4-year lead, not through scientific breakthroughs, but through extreme efficiency in clinical trial execution — this is the core competency of large pharma and a capability analysts should prioritize in their assessments. (Ashwin Varma)
3. The pharmaceutical industry is a classic case of "high margins + high volatility": gross margins >70%, but R&D expenses account for 20% of revenue (the highest among industries), and R&D is not capitalized, leading to extreme variance in ROIC — excellent when good, terrible when bad. (Ashwin Varma)
4. Revenue erosion after biologic patent expiry is far slower than for small molecules — 80% of small-molecule revenue disappears within 8 months (e.g., Seroquel), while biologics can sustain revenue for years (e.g., insulin), though political pressure (e.g., the IRA) may alter this pattern. (Ashwin Varma)
5. Large pharma's "special sauce" is shifting from internal science to external asset identification — in 1995, 70% of industry revenue came from internal R&D; today, 50-60% comes from external acquisitions, and 70-80% of Merck's own pipeline comes from acquisitions. (Ashwin Varma)
6. Merck's post-Keytruda strategy rests on "three legs" — pulmonary hypertension, autoimmune, and ADC — the direction is correct, but historical patterns show that every large pharma has struggled when facing a patent cliff (Pfizer/Lipitor, Merck itself in the 2000s), and investors need to "face the challenges soberly." (Ashwin Varma)
7. The "dual-engine" relationship between the CEO and the R&D head is more important than a single CEO — the combination of Frazier (lawyer) + Perlmutter (scientist) was key to Merck's success in the Keytruda era, while the chemistry of the new pair, Davies + Dean, remains to be tested. (Ashwin Varma)
8. Analysis of pharmaceutical companies should center on product lifecycle positioning: is it a "pipeline-driven period" before patent expiry or a "growth-driven period" after patent expiry — the core questions for each phase are entirely different, giving pharma a more "structured" analytical advantage compared to other industries. (Ashwin Varma)